CBD supplementation reduces arterial blood pressure via modulation of the sympatho-chromaffin system: A substudy from the HYPER-H21-4 trial

Kumrić, Marko; Dujic, Goran; Vrdoljak, Josip; Svagusa, Karla; Kurir, Tina Tičinović; Šupe‐Domić, Daniela; Dujić, Željko; Božić, Joško

doi:10.1016/j.biopha.2023.114387

Cited by 10 publications

(7 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In accordance with our results, it was found in a recent CATSTAT-HF study that patients in a higher NYHA functional class had higher serum catestatin levels [ 52 ]. Our findings agree with a prior study showing an inverse relationship between serum catestatin levels and disease severity [ 53 , 54 ]. More recently, Martins et al reported that long-term AF with a duration of up to 1 year and transition to persistent arrhythmia was accompanied by progressively increasing atrial dilation, mitral valve regurgitation, myocyte hypertrophy, and atrial fibrosis [ 55 ].…”

Section: Discussionsupporting

confidence: 93%

Serum Catestatin Concentrations Are Increased in Patients with Atrial Fibrillation

Katić

Jurišić

Kumrić

et al. 2023

JCDD

Self Cite

View full text Add to dashboard Cite

The autonomic nervous system is crucial in initiating and maintaining atrial fibrillation (AF). Catestatin is a multipurpose peptide that regulates cardiovascular systems and reduces harmful, excessive activity of the sympathetic nervous system by blocking the release of catecholamines. We aimed to determine whether serum catestatin concentrations are associated with AF severity, duration indices, and various clinical and laboratory indicators in these individuals to better define the clinical value of catestatin in patients with AF. The present single center study enrolled 73 participants with AF and 72 healthy age-matched controls. Serum catestatin concentrations were markedly higher in AF patients than controls (14.11 (10.21–26.02) ng/mL vs. 10.93 (5.70–20.01) ng/mL, p = 0.013). Furthermore, patients with a more severe form of AF had significantly higher serum catestatin (17.56 (12.80–40.35) vs. 10.98 (8.38–20.91) ng/mL, p = 0.001). Patients with higher CHA2DS2-VASc scores (17.58 (11.89–37.87) vs. 13.02 (8.47–22.75) ng/mL, p = 0.034) and higher NT-proBNP levels (17.58 (IQR 13.91–34.62) vs. 13.23 (IQR 9.04–22.61), p = 0.036) had significantly higher serum catestatin concentrations. Finally, AF duration correlated negatively with serum catestatin levels (r = −0.348, p = 0.003). The results of the present study implicate the promising role of catestatin in the intricate pathophysiology of AF, which should be explored in future research.

show abstract

Section: Discussionsupporting

confidence: 93%

Serum Catestatin Concentrations Are Increased in Patients with Atrial Fibrillation

Katić

Jurišić

Kumrić

et al. 2023

JCDD

Self Cite

View full text Add to dashboard Cite

show abstract

“…Nevertheless, it is reasonable to assume that the recreational use of cannabis in more or less frequent users is due to the presence, in the self-administered substance, of predominant amounts of THC, possibly followed by CBD, since the presence of high amounts of CBD in cannabis preparations have been described to considerably reduce the psychotropic properties of THC. 36 Both THC and CBD, via different mechanisms and receptors, are known to reduce MAP in both humans and laboratory animals, [37][38][39] and hence the present finding of a positive correlation between frequency of cannabis use and higher PP, which should lead to higher MAP values, is counterintuitive. It is possible that chronic activation of CB1 by THC leads to its desensitization, and hence to higher MAP, a mechanism previously proposed also for the association between cannabis use and lower BMI and reduced incidence of type 2 diabetes despite the well-known positive effects of CB1 activation on energy balance.…”

Section: Possible Biological Pathways (Mechanisms) Between Cannabis U...mentioning

confidence: 67%

Cannabis use in relation to Pulse Pressure and Mean Arterial Pressure in US Adults

Ruddy

Marzo

Ngueta

2023

Preprint

View full text Add to dashboard Cite

Background: Pulse pressure (PP) and mean arterial pressure (MAP) have been well-established as markers of cardiovascular risk in clinical settings. We aimed to determine the impact of cannabis use on both PP and MAP in U.S. adults and to assess the modifying role of sex. Methods: We abstracted data from the 2009 to 2018 National Health and Nutrition Examination survey (NHANES). Cannabis use was assessed by NHANES professionals in adults aged 18 to 59 years by using computer-assisted self-interviews. We defined PP as the difference between systolic and diastolic BP, and MAP as diastolic BP plus one third of PP. We used multivariable linear models to estimate the covariates-adjusted associations and assessed effect modification by including sex×exposure interaction terms into the model. Results: The mean age of the study population (n=8,942) was 35.0±11.9 years, with 51% female (n=4,551). Mean±SD PP and MAP were 46±13 mm Hg and 82±13 mm Hg, respectively. We found a significant interaction between sex and cannabis use in relation to PP (P=0.0878) and no interaction when modeling MAP (P=0.2084). The mean difference of PP between cannabis users and never-users increased with the frequency of use per week, being +4.5 mm Hg (P=0.0004) in those who reported 1 use/week, +4.9 mm Hg (P<0.0001) for 2-3 uses/week and +4.9 mm Hg (P<0.0001) for ≥ 4 uses/week. In females, only those who reported ≥ 4 uses/week showed a higher PP (+3.1 mm Hg; P=0.0050) compared with never-users. Conclusions: In US adults aged 18 to 59 years, cannabis use is associated with widening of PP in males.

show abstract

“…However, the effect on diastolic blood pressure and MAP lowering was most evident at that time. Because of the improved properties of DehydraTECH™2.0 CBD, bioabsorption and bioavailability are increased [ 19 , 20 , 21 ]. Perhaps it is reasonable to infer that the maximum concentration, and hence the effect, is reached sooner.…”

Section: Discussionmentioning

confidence: 99%

“…For instance, faster and higher absorption of CBD was shown in young volunteers after oral TurboCBD™ formulation, which led to a decrease in diastolic and mean arterial pressure and increase in cerebral perfusion [ 19 ]. In this study, we used DehydraTECH™2.0 CBD, a patented capsule that advances the earlier TurboCBD™ formulation (developed by Lexaria Bioscience Corp., Kelowna, BC, Canada) and increases the bioabsorption of the active content due to its enhanced lipophilic composition by bypassing (or reducing) first-pass liver metabolism [ 19 , 20 , 21 ]. The bioavailability of CBD in subjects depends also on the rate of metabolism associated with the genetic variability of cytochrome P450: CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2C19*3, CYP2C19*7 and CYP3A4 genes [ 22 , 23 , 24 , 25 , 26 , 27 , 28 ].…”

Section: Introductionmentioning

confidence: 99%

Trial of a Novel Oral Cannabinoid Formulation in Patients with Hypertension: A Double-Blind, Placebo-Controlled Pharmacogenetic Study

Batinic¹,

Sutlović

Kuret

et al. 2023

Pharmaceuticals

Self Cite

View full text Add to dashboard Cite

Cannabidiol (CBD) is a non-psychoactive cannabinoid, and available evidence suggests potential efficacy in the treatment of many disorders. DehydraTECH™2.0 CBD is a patented capsule formulation that improves the bioabsorption of CBD. We sought to compare the effects of CBD and DehydraTECH™2.0 CBD based on polymorphisms in CYP P450 genes and investigate the effects of a single CBD dose on blood pressure. In a randomized and double-blinded order, 12 females and 12 males with reported hypertension were given either placebo capsules or DehydraTECH™2.0 CBD (300 mg of CBD, each). Blood pressure and heart rate were measured during 3 h, and blood and urine samples were collected. In the first 20 min following the dose, there was a greater reduction in diastolic blood pressure (p = 0.025) and mean arterial pressure MAP (p = 0.056) with DehydraTECH™2.0 CBD, which was probably due to its greater CBD bioavailability. In the CYP2C9*2*3 enzyme, subjects with the poor metabolizer (PM) phenotype had higher plasma CBD concentrations. Both CYP2C19*2 (p = 0.037) and CYP2C19*17 (p = 0.022) were negatively associated with urinary CBD levels (beta = −0.489 for CYP2C19*2 and beta = −0.494 for CYP2C19*17). Further research is required to establish the impact of CYP P450 enzymes and the identification of metabolizer phenotype for the optimization of CBD formulations.

show abstract

CBD supplementation reduces arterial blood pressure via modulation of the sympatho-chromaffin system: A substudy from the HYPER-H21-4 trial

Cited by 10 publications

References 38 publications

Serum Catestatin Concentrations Are Increased in Patients with Atrial Fibrillation

Serum Catestatin Concentrations Are Increased in Patients with Atrial Fibrillation

Cannabis use in relation to Pulse Pressure and Mean Arterial Pressure in US Adults

Trial of a Novel Oral Cannabinoid Formulation in Patients with Hypertension: A Double-Blind, Placebo-Controlled Pharmacogenetic Study

Contact Info

Product

Resources

About